Weight-Loss Jabs Linked to Lower Dementia, Stroke Risk in 60,000 Patients

Recent studies indicate that weight loss injections containing GLP-1 receptor agonists, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), may provide neuroprotective benefits, reducing the risk of dementia by 37% and stroke by 19% in people with type 2 diabetes and obesity. The research, analyzing data from 60,000 individuals over seven years, also found a 30% lower risk of premature death among users of these drugs, with even greater benefits observed in older adults, women, and those with a BMI of 30 to 40. While these medications are known for managing weight and blood sugar, new evidence suggests they may improve long-term cognitive and survival outcomes, though experts stress that randomized clinical trials are necessary to confirm these protective effects. No significant differences were found regarding Parkinson’s disease or brain bleeds. Additionally, a separate study on dosing of Mounjaro found that lower doses, such as 7.5mg, may lead to greater weight loss with fewer side effects compared to the highest 15mg dose, highlighting individual variability in treatment response. Researchers emphasize the need for further studies to validate these findings and explore their implications beyond patients with diabetes and obesity.